Table 1

Study characteristics of included trials

Study, yearNo. of patients*Duration of treatment (weeks)Treatment comparisons (μg)Mean ageMale %Current smoker %Baseline FEV1%†Baseline FEV1 (L)‡
Buhl et al 201519516252TIO/OLO 5/5
TIO/OLO 2.5/5
TIO 5
TIO 2.5
OLO 5
64.0733750.01.17
Celli et al 201420148924UMEC/VI 125/25
UMEC 125
VI 25
Placebo
62.9655248.21.28
Decramer et al 20142184324UMEC/VI 125/25
UMEC/VI 62.5/25
VI 25
TIO 18
62.9695147.71.31
Decramer et al 20142186924UMEC/VI 125/25
UMEC/VI 62.5/25
UMEC 125
TIO 18
64.6684547.11.16
D'Urzo et al 201422166924ACL/FM 400/12
ACL/FM 400/6
ACL 400
FM 12
Placebo
63.9535253.51.36
Donohue et al 20143156252UMEC/VI 125/25
UMEC 125
Placebo
61.3676354.71.49
Maleki-Yazdi et al 20142390524UMEC/VI 62.5/25
TIO 18
62.3685746.31.41§
Singh et al 201424172924ACL/FM 400/12
ACL/FM 400/6
ACL 400
FM 12
Placebo
63.2684754.31.41
Vincken et al 20142544712IND/Glyco 110/50
IND 150
63.6814254.91.46
ZuWallack et al 201426§ (ANHELTO 1 and 2)226712TIO/OLO 18/5
TIO 18
64.3524953.71.25
Bateman et al 201327213526IND/Glyco 110/50
IND 150
Glyco 50
TIO 18
Placebo
63.9754055.21.30
Dahl et al 20132833852IND/Glyco 110/50
Placebo
62.6774557.41.45
Donohue et al 201329153224UMEC/VI 62.5/25
UMEC 62.5
VI 25
Placebo
63.1715047.41.23
Wedzicha et al 201330220564IND/Glyco 110/50
Glyco 50
TIO 18
63.3753837.20.90
DB2114417 20123264112UMEC/VI 125/25
UMEC/VI 62.5/25
VI 25
UMEC 125
UMEC 62.5
Placebo
61.65663NR1.44
DB2114418 20123355412UMEC/VI 125/25
UMEC/VI 62.5/25
VI 25
UMEC 125
UMEC 62.5
Placebo
62.65561NR1.32
Mahler et al 201234113112TIO 18 /IND 150
TIO 18
63.7693848.61.15
Mahler et al 201234114212TIO 18 /IND 150
TIO 18
63664048.61.14
Novartis A1301 20123515852IND/Glyco 110/50
TIO 18
69.396NRNR1.33¶
Tashkin et al 20093624312TIO 18 /FM 12
TIO 18
63.96647NRNR
Vogelmeier et al 20083784724TIO 18 /FM 10
FM 10
TIO 18
Placebo
62.678NR511.5
Aaron et al 20073830452TIO 18/SAL 50
TIO 18
67.9562641.71.01
  • *Number of patients included in this analysis.

  • †Postbronchodilator.

  • ‡Prebronchodilator.

  • §Includes 2 trials making a total of 23 trials.

  • ¶At week 3.

  • ACL, aclidinium; FM, formoterol; Glyco, glycopyrronium; IND, indacaterol; NR, not reported; OLO, olodaterol; SAL, salmeterol; TIO, tiotropium; UMEC, umeclidinium; VI, vilanterol.